56
Participants
Start Date
January 16, 2023
Primary Completion Date
July 11, 2025
Study Completion Date
July 11, 2025
RO7303509
RO7303509 will be administered as SC injection monthly, as specified in each treatment group.
Placebo
RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.
UZ Leuven, Leuven
Institute of Rheumatology Belgrade - PPDS, Belgrade
Military Medical Academy, Belgrade
Hopital Purpan, Toulouse
CHU de Bordeaux, Pessac
CHRU Rennes, Rennes
Centre Hospitalier Universitaire de Grenoble - Albert Michallon, La Tronche
Hospital Quironsalud Infanta Luisa, Seville
Hopitaux Universitaires, Strasbourg
Hopital Cochin, Paris
Stanford University, Palo Alto
Rambam Medical Center - PPDS, Haifa
Meir Medical Center, Kfar Saba
Hospital For Special Surgery, New York
Metroplex Clinical Research Centre, Dallas
Hospital de Alta Complejidad en Red ?El Cruce? Dr. Néstor Kirchner ? S.A.M.I.C., Buenos Aires
Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz
Zespol Poradni Specjalistycznych REUMED, Lublin
Hospital Garcia de Orta, Almada
Centro Hospitalar E Universitário de Coimbra EPE, Coimbra
The Alliance Medical Sciences Campus, San Juan
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall d Hebron, Barcelona
Royal Free Hospital, London
Lead Sponsor
Genentech, Inc.
INDUSTRY